Hilco Streambank (“Hilco”) is seeking offers to acquire the intellectual property assets of AigenPulse Limited (In Administration) (“AigenPulse” or the “Company”) on behalf of the Joint Administrators of the Company, Matt Haw and Janet Burt of RSM Restructuring Advisory LLP.
AigenPulse is an innovative and dynamic company at the intersection between life sciences and data technology. Founded in 2016, the aim of the Company was to streamline the drug discovery process by combining machine learning and human expertise.
Management of the Company advise that there are a number of challenges drug discovery companies face, such as the time-consuming manual analyses of highly complex data, low precision and reproducibility of data, and challenges in adhering to compliance processes. The Company developed the bespoke AigenPulse platform in order to address these challenges.
The AigenPulse platform is a series of interrelated systems designed to create efficiencies within the life sciences research sector. A selection of these efficiencies is summarised below:
- 100% reproducibility of data using automated supervised gating and workspace templating. The system is also GxP aligned for use in clinical development, including full audit trails.
- Processing 100s of datasets simultaneously and at scale, freeing up scientists for higher value tasks. The suite also allows for automatic QA/QC on datasets providing clarity on data quality.
- Retaining pipeline and data integration pipelines to ensure 100% reproducibility. Data is automatically parsed and integrated to be usable in analyses and visualisations.
Prior to the Company’s Administration, management advise that the AigenPulse platform had won a contract from one of the world’s premier biopharmaceutical companies, reducing the data analysis process as part of a cancer study by up to 50%.
The Company has generated circa £2m in revenue since its inception and was profitable prior to its Administration, with net profit of circa £275k in 2018.
The AigenPulse Platform
The Aigenpulse platform is a state-of-the-art data intelligence solution that is designed to help expedite the drug discovery and development process. The platform harnesses the latest artificial intelligence and machine learning tools to deliver advanced data analytics to underpin scientific decision making.
The platform features an API service allowing connection to third-party systems, sources and software that are typically used within the life sciences industry.
Technical Organisational Knowledge
The AigenPulse platform has been created with the life sciences in mind. AigenPulse has various documentation explaining how the AigenPulse platform works and how various suites can be used to create efficiencies in workflows.
The AigenPulse platform and processes align to GxP/GAMP5 guidelines, are ISO 27001 and ISO 9001 certified as well as FDA 21 CFR 11 Compliant.
Goodwill in the AigenPulse Brand
AigenPulse is known within the drug discovery industry, having raised circa £3.6m in investment since 2019 and working closely with a leading biopharmaceutical company in cancer research.
Registered Trade Mark
The Company has three registered trade marks protecting the AigenPulse name and logo. A UK trademark (UK00917335531), an EUIPO trade mark (017335531), and a USPTO trade mark (87674387). These trade marks cover the medical service and scientific research sectors.
Website Content & Social Media Content
The Company’s website is hosted at www.aigenpulse.com and features information on the Company’s products, testimonials and thought leadership blogs.
Rights in the social media accounts are also available across Facebook, Instagram and LinkedIn.
Offers are due January 28, 2022 at 4pm GMT.
All expressions of interest and bids are to be directed to Hilco in writing. A Bid Submission Form is available on request. Please contact Hilco to gain access to a virtual data room of further information on signing a confidentiality agreement.
Key Terms & Conditions
The Joint Administrators act as an agent of the Company and without personal liability.
The bidder acknowledges that Hilco acts as an agent for the Joint Administrators who offers for sale only what right, title and interest (if any) the Company possesses in the assets. Such sale will be without any warranties, expressed or implied. The information provided has not been verified by Hilco or the Joint Administrators and bidders are deemed to have carried out their own due diligence.
VAT, if applicable, at 20% will be added to the price. A buyer’s premium of 10% of the sale price is payable by the winning bidder. Hilco Streambank’s full Terms and Conditions apply.